{"Symbol": "AKTX", "AssetType": "Common Stock", "Name": "Akari Therapeutics PLC", "Description": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.", "CIK": "1541157", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "22 BOSTON WHARF ROAD, BOSTON, MA, UNITED STATES, 02210", "OfficialSite": "https://www.akaritx.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-06-30", "MarketCapitalization": "16962900", "EBITDA": "-12783000", "PERatio": "0", "PEGRatio": "0", "BookValue": "0.785", "DividendPerShare": "None", "DividendYield": "None", "EPS": "0", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.286", "ReturnOnEquityTTM": "-1.12", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "4.533", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "2", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "0.367", "EVToRevenue": "-", "EVToEBITDA": "-0.0639", "Beta": "0.255", "52WeekHigh": "1.73", "52WeekLow": "0.218", "50DayMovingAverage": "0.826", "200DayMovingAverage": "1.067", "SharesOutstanding": "32614700", "SharesFloat": "15835104000", "PercentInsiders": "31.477", "PercentInstitutions": "3.746", "DividendDate": "None", "ExDividendDate": "None"}